# DESCRIPTION

## GOVERNMENT FUNDING

- disclose government funding

## BACKGROUND OF THE INVENTION

- describe limitations of homologous recombination

## SUMMARY OF THE INVENTION

- introduce fusion protein
- describe guide nucleotide sequence-programmable DNA binding protein domain
- describe recombinase catalytic domain
- describe optional linker
- describe guide nucleotide sequence-programmable DNA binding protein domain options
- describe recombinase catalytic domain options
- describe linker options
- describe nuclear localization signal domain
- describe affinity tag options
- describe fusion protein structure
- describe fusion protein sequence identity
- describe dimer of fusion protein
- describe dimer binding to target DNA
- describe tetramer of fusion protein
- describe tetramer binding to target DNA
- describe method for site-specific recombination
- describe method for site-specific recombination between two DNA molecules
- describe method for site-specific recombination within a single DNA molecule
- describe deletion of a region of the DNA molecule
- describe recombination in a cell
- describe kit for expressing fusion protein

## DEFINITIONS

- define singular and plural forms
- introduce RNA-programmable DNA-binding proteins
- describe Cas9 nucleases
- explain CRISPR system
- define Cas9 nickases
- describe inactive Cas9 (dCas9)
- introduce variants of dCas9
- describe methods for generating inactive Cas9
- explain DNA cleavage domains of Cas9
- introduce Cas9 variants
- describe homology to wild-type Cas9
- introduce PAM motif
- describe recognition of PAM sequences
- introduce non-canonical PAM sequences
- describe Cas9 domains with altered PAM specificities
- introduce other RNA-programmable DNA-binding proteins
- define nuclease-inactive Cpf1 variants
- describe mutations inactivating Cpf1 nuclease activity
- introduce Argonaute protein from Natronobacterium gregoryi
- describe NgAgo-gDNA system without PAM requirement
- introduce Cas9 variants with relaxed PAM requirements
- describe mutations relaxing PAM requirements
- introduce additional Cas9 proteins and variants
- describe CasX and CasY proteins
- define conjugating, conjugated, and conjugation
- define consensus sequence
- define engineered
- define effective amount
- define guide nucleotide sequence-programmable DNA-binding protein
- define linker
- describe linker properties
- define mutation
- describe mutation methods
- define nuclear localization sequence
- describe nuclease properties
- define nucleic acid
- describe nucleic acid properties
- define orthogonal
- define pharmaceutical composition
- define proliferative disease
- define protein, peptide, and polypeptide
- define fusion protein
- define pseudo-gix site and other pseudo-sites
- define RNA-programmable nuclease and RNA-guided nuclease
- describe gRNA structure and function
- describe RNA-programmable nuclease:RNA complex
- describe guide nucleotide sequence-programmable DNA binding protein
- define recombinase and describe its function
- describe serine and tyrosine recombinases
- describe Gin recombinase and its catalytic domain
- define recombinase
- motivate applications of recombinases
- summarize recombinase examples
- describe recombinase engineering
- introduce nuclease-inactivated RNA-programmable nucleases
- define recombine and recombination
- define recombinant
- define subject
- define target nucleic acid and target genome
- provide additional definitions
- define target site
- describe target site structure
- define Transcriptional Activator-Like Effector (TALE)
- describe TALE DNA binding domain
- define Transcriptional Activator-Like Element Nuclease (TALEN)
- describe TALEN DNA cleavage domain
- define treatment
- describe treatment goals
- define vector
- describe vector characteristics
- define zinc finger
- describe zinc finger structure
- define zinc finger nuclease
- describe zinc finger nuclease structure
- describe zinc finger nuclease function
- describe zinc finger nuclease design
- describe zinc finger nuclease applications

## DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

- introduce embodiments

### Guide Nucleotide Sequence-Programmable DNA Binding Protein

- introduce programmable DNA binding protein domain
- describe guide nucleotide sequence-programmable DNA binding protein
- specify dCas9 and Cas9 nickase embodiments
- provide amino acid sequence identity percentages
- describe variants and homologues of dCas9 and Cas9 nickase
- introduce additional suitable nuclease-inactive dCas9 domains
- describe Cas9 domain with decreased electrostatic interactions
- introduce PAM motif and its recognition by Cas9
- describe different PAM specificities of various Cas9 nucleases
- introduce RNA-programmable DNA binding proteins
- describe Cpf1 as an RNA-programmable DNA-binding protein
- introduce guide nucleotide sequence-programmable DNA binding protein
- describe Cpf1 protein
- describe mutations inactivating Cpf1 nuclease activity
- describe C2c1, C2c2, and C2c3 proteins
- describe structural comparisons between C2c1 ternary complexes and Cas9 and Cpf1 counterparts
- describe NgAgo protein
- describe PAMless Cas9 variants
- describe linkers
- describe flexible linkers
- describe rigid linkers
- describe XTEN linker
- describe other linker sequences
- describe linker lengths and weights
- describe peptide linkers
- describe non-peptide linkers
- describe alkyl linkers

### Recombinase Catalytic Domain

- introduce recombinase catalytic domain
- list suitable recombinases
- describe mutations in recombinases
- specify sequence identity of mutated recombinases
- introduce evolved recombinases
- describe altered target sequence preferences
- specify sequence identity of evolved recombinases
- describe recognition of non-canonical target sequences
- specify number of nucleotide differences
- introduce use of portions of recombinases
- specify use of C-terminal portion of Cre recombinase
- describe truncation of Cre recombinase
- specify truncation positions
- describe recombinase target sequence length
- specify canonical recombinase target sequences
- describe evolved recombinase recognition of natural sequences
- specify recognition of sequences in mammalian genomes
- describe recognition of sequences in safe harbor genomic loci
- provide additional references for suitable recombinases

### Structure of the Fusion Protein

- define fusion protein structure
- list exemplary fusion protein structures
- describe recombinase catalytic domain structure
- describe guide nucleotide sequence-programmable DNA binding protein domain structure
- describe linker sequence structure
- describe NLS domain structure
- describe affinity tag structure
- describe bifurcated or circularly permuted guide nucleotide sequence-programmable DNA binding protein domain structure
- describe fusion protein with optional affinity tag
- describe fusion protein with optional NLS domain
- describe fusion protein with optional linker sequence
- describe fusion protein with recombinase catalytic domain and guide nucleotide sequence-programmable DNA binding protein domain
- describe fusion protein with N-terminal portion of bifurcated or circularly permuted guide nucleotide sequence-programmable DNA binding protein domain
- describe fusion protein with C-terminal portion of bifurcated or circularly permuted guide nucleotide sequence-programmable DNA binding protein domain
- describe fusion protein structure
- provide alternative fusion protein structures
- describe affinity tags
- list suitable affinity tags
- describe third linker
- provide examples of third linker sequences
- describe non-peptide linkers
- specify sequence identity of fusion protein
- describe LSR structure
- define left-half site and right-half site
- specify spacer sequence length
- provide examples of spacer sequence lengths

## EXAMPLES

### Example 1: A Programmable Cas9-Serine Recombinase Fusion Protein that Operates on DNA Sequences in Mammalian Cells

- introduce materials and methods
- describe oligonucleotides and PCR
- outline reporter construction
- describe plasmid construction
- detail plasmid sequencing experiments
- describe cell culture and transfection
- outline flow cytometry
- identify genomic target sites
- describe DNA sequencing
- analyze recCas9 catalyzed genomic deletions
- detail reporter assembly
- describe plasmid construction for recCas9
- outline guide RNA expression vector construction
- describe plasmid modification for sequencing experiments
- detail cell culture and transfection for sequencing experiments
- describe episomal DNA extraction
- outline DNA sequencing analysis
- calculate limit of detection
- introduce programmable Cas9-Serine recombinase fusion protein
- describe minimum deletion efficiency
- motivate use of limiting dilution of genomic template
- describe results of primary PCR and nested PCR
- fuse Gin Recombinase to dCas9
- describe construction of reporter plasmid
- vary parameters influencing recCas9 components
- describe results of varying recCas9 components
- target DNA sequences found in human genome with recCas9
- identify potential target sites in human genome
- test recCas9 activity on PCDH15 site
- determine requirement for both guide RNA sequences
- test orthogonality of recCas9
- evaluate recCas9 activity on multiple target sites
- characterize recCas9 products
- sequence reporter plasmids
- analyze sequencing data
- test for mutagenesis
- measure deletion products
- establish recCas9-mediated recombination
- investigate recCas9-mediated genomic deletion
- design guide RNA expression vectors
- detect chromosomal deletion events
- estimate genomic deletion efficiency
- use alternative recombinases
- fuse Cre recombinase to dCas9
- test truncated Cre recombinase fusions

## EQUIVALENTS AND SCOPE

- describe scope of invention
- discuss equivalents to specific embodiments
- clarify meaning of articles and conjunctions in claims
- discuss variations and combinations of claims

